Valeant Pharmaceuticals International Inc. (NYSE:VRX) had its price objective reduced by Royal Bank Of Canada from $36.00 to $35.00 in a report issued on Wednesday. Royal Bank Of Canada currently has a sector perform rating on the specialty pharmaceutical company’s stock.

A number of other research firms have also recently issued reports on VRX. Wells Fargo & Co. reissued a sell rating on shares of Valeant Pharmaceuticals International in a research report on Monday, June 20th. JPMorgan Chase & Co. reissued a hold rating and set a $35.00 price objective (down previously from $50.00) on shares of Valeant Pharmaceuticals International in a research report on Wednesday, June 22nd. BMO Capital Markets initiated coverage on shares of Valeant Pharmaceuticals International in a research report on Tuesday, June 28th. They set a market perform rating and a $26.00 price objective on the stock. Stifel Nicolaus restated a buy rating and issued a $55.00 target price on shares of Valeant Pharmaceuticals International in a report on Wednesday, July 6th. Finally, Rodman & Renshaw restated a buy rating and issued a $90.00 target price on shares of Valeant Pharmaceuticals International in a report on Wednesday, July 6th. Six research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. Valeant Pharmaceuticals International currently has a consensus rating of Hold and a consensus target price of $56.49.

Valeant Pharmaceuticals International (NYSE:VRX) traded down 2.47% during trading on Wednesday, reaching $22.13. The company had a trading volume of 6,071,396 shares. Valeant Pharmaceuticals International has a one year low of $18.55 and a one year high of $179.83. The company has a 50-day moving average price of $27.08 and a 200 day moving average price of $26.92. The company’s market capitalization is $7.69 billion.

Valeant Pharmaceuticals International (NYSE:VRX) last issued its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $1.40 EPS for the quarter, missing the Zacks’ consensus estimate of $1.48 by $0.08. The firm had revenue of $2.42 billion for the quarter, compared to the consensus estimate of $2.47 billion. Valeant Pharmaceuticals International had a negative net margin of 9.29% and a positive return on equity of 46.59%. The business’s revenue was down 11.4% compared to the same quarter last year. During the same period last year, the company posted $2.14 EPS. Analysts expect that Valeant Pharmaceuticals International will post $6.53 earnings per share for the current year.

In other Valeant Pharmaceuticals International news, Director Argeris N. Karabelas acquired 4,000 shares of the stock in a transaction on Thursday, August 11th. The stock was acquired at an average price of $24.65 per share, for a total transaction of $98,600.00. Following the completion of the transaction, the director now directly owns 20,726 shares of the company’s stock, valued at $510,895.90. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 16.37% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the stock. Acrospire Investment Management LLC bought a new position in Valeant Pharmaceuticals International during the first quarter valued at approximately $108,000. Tower Research Capital LLC TRC increased its position in Valeant Pharmaceuticals International by 6.7% in the second quarter. Tower Research Capital LLC TRC now owns 6,405 shares of the specialty pharmaceutical company’s stock valued at $129,000 after buying an additional 402 shares in the last quarter. Cacti Asset Management LLC increased its position in Valeant Pharmaceuticals International by 68.0% in the second quarter. Cacti Asset Management LLC now owns 8,400 shares of the specialty pharmaceutical company’s stock valued at $169,000 after buying an additional 3,400 shares in the last quarter. AGF Investments Inc. increased its position in Valeant Pharmaceuticals International by 121.9% in the second quarter. AGF Investments Inc. now owns 8,842 shares of the specialty pharmaceutical company’s stock valued at $178,000 after buying an additional 4,857 shares in the last quarter. Finally, NN Investment Partners Holdings N.V. bought a new position in Valeant Pharmaceuticals International during the first quarter valued at approximately $200,000. Institutional investors and hedge funds own 63.59% of the company’s stock.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

5 Day Chart for NYSE:VRX

Receive News & Stock Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related stocks with our FREE daily email newsletter.